Grow your business safely with LABO PHARMA CONSEILS

All the information you need about LABO PHARMA CONSEILS to develop and secure your business in France

L HOME > CORPORATES > LABO PHARMA CONSEILS > BALANCE SHEET ( 2020-07-27)

THE LIST OF BALANCE SHEET : LABO PHARMA CONSEILS

CORPORATEBOBACCESTABLISHMENTSMANAGERSFINANCE
Deposit Confidentiality closing date document
2023-05-05 Public 2022-12-31 Complete
2022-06-03 Public 2021-12-31 Complete
2021-12-15 Public 2020-09-30 Complete
2020-07-27 Public 2019-09-30 Complete
NameLABO PHARMA CONSEILS
Siren494753031
Closing2019-09-30
Registry code 2104
Registration number 5209
Management number2018B01291
Activity code 7022Z
Closing date n-12018-12-31
Duration Fiscal year 09
Duration Fiscal year n-112
Filing date2020-07-27
Modification00 Annual accounts entered without anomaly
Balance sheet typeC : Complete
Currency codeEUR
ConfidentialityPublic
Address21000 DIJON
1 - Assets (balance sheet)Gross amount year NAmortization year NNet year NNet year N-1
BH Other financial assets 2 750.00 2 750.00 2 750.00
BJ TOTAL (I) 2 750.00 2 750.00 2 750.00
BV Advances and down payments on orders 1 920.00 1 920.00 1 920.00
BX Customers and related accounts 23 200.00 23 200.00 23 200.00
BZ Other receivables 15 847.00 15 847.00 15 847.00
CF Cash and cash equivalents 26 692.00 26 692.00 26 692.00
CJ TOTAL (II) 67 659.00 67 659.00 67 659.00
CO Grand total (0 to V) 70 409.00 70 409.00 70 409.00
2 - Liabilities (balance sheet)Amount year NAmount year N-1
DA Share or individual capital 11 000.00 11 000.00 11 000.00
DD Legal reserve (1) 1 100.00 1 100.00 1 100.00
DH Retained earnings 11 458.00 13 970.00 11 458.00
DI RESULTS FOR THE YEAR (Profit or Loss) 623.00 -2 512.00 623.00
DL TOTAL (I) 24 181.00 23 558.00 24 181.00
DV Miscellaneous Loans and Financial Debts (4) 1 351.00 1 351.00
DX Trade payables and related accounts 18 705.00 2 585.00 18 705.00
DY Tax and social security liabilities 5 109.00 5 109.00
EB Prepaid income (2) 21 063.00 21 063.00
EC TOTAL (IV) 46 228.00 2 585.00 46 228.00
EE Grand total (I to V) 70 409.00 26 143.00 70 409.00
3 - Income statementAmount France year NAmount Export year NTotal year NTotal year N-1
FG Production sold - services 112 052.00
FJ Net sales 112 052.00
FR Total operating income (I) 112 052.00
FU Purchases of raw materials and other supplies 609.00
FW Other purchases and external expenses 110 709.00
FX Taxes, duties, and similar payments 101.00
GE Other Expenses 1.00
GF Total Operating Expenses (II) 111 420.00
GG - OPERATING RESULT (I - II) 633.00
GP Total financial income (V)
GU Total financial expenses (VI) 9.00
GV - FINANCIAL INCOME (V - VI) -9.00
GW - CURRENT INCOME BEFORE TAX (I - II + III - IV + V - VI) 623.00
4 - Income statement (continued)Amount year NAmount year N-1
HL TOTAL REVENUE (I + III + V + VII) 112 052.00 106 889.00 112 052.00
HM TOTAL EXPENSES (II + IV + VI + VIII + IX + X) 111 429.00 109 401.00 111 429.00
HN PROFIT OR LOSS (Total revenue - Total expenses) 623.00 -2 512.00 623.00
5 - Fixed assets increase - decreaseGross value at beginning of year - Item by itemRevaluation - DisposalsAcquisition - Gross value at year-end
0G ACQUISITIONS Total General Total 2 750.00
I3 DECREASES Total Financial Fixed Assets 2 750.00
I4 DECREASES Grand Total 2 750.00
LQ ACQUISITIONS Total Financial Fixed Assets 2 750.00
8 - Receivables and payablesGross amountAmount within 1 yearAmount 1 to 5 yearsAmount more than 5 years
8B Suppliers and Related Accounts 18 705.00 18 705.00 18 705.00
8D Social Security and Other Social Organizations 5 109.00 5 109.00 5 109.00
8L Deferred income 21 063.00 21 063.00 21 063.00
UT Other financial assets 2 750.00 2 750.00 2 750.00
UX Other trade receivables 23 200.00 23 200.00 23 200.00
VI Group and Associates 1 351.00 1 351.00 1 351.00
VR Miscellaneous debtors (including receivables related to repo transactions) 15 847.00 15 847.00 15 847.00
VT TOTAL – STATEMENT OF RECEIVABLES 41 797.00 39 047.00 2 750.00 41 797.00
VY TOTAL – STATEMENT OF LIABILITIES 46 228.00 46 228.00 46 228.00

all companies in France

Complete and comprehensive database.